First Report Managed Care

Your Go-To Resource for the Latest Developments in the Rapidly Changing Sector of Managed Care
Email: [email protected]

[First Report Managed Care @FirstReportMC]

Happening today at 12 PM ET: join us live for expert perspectives on IgA nephropathy.

This webinar will explore emerging therapies, access considerations, and key managed care implications in a rare and evolving disease state.

Register now: https://t.co/C2PIJ93Mua

[First Report Managed Care @FirstReportMC]

Happening this week: join us live on April 30 at 12 PM ET for expert perspectives on IgA nephropathy.

This webinar will explore emerging therapies, access considerations, and key managed care implications in a rare and evolving disease state.

Register: https://t.co/VOoawMQvM5

[First Report Managed Care @FirstReportMC]

1 week to go: Join us live on April 30 at 12 PM ET for expert perspectives on emerging therapies, access considerations, and managed care implications in IgA nephropathy.

Register: https://t.co/cs6fYg3jcL

[First Report Managed Care @FirstReportMC]

Join Russell Spjut, PharmD and Matthew R. Weir, MD for expert perspectives on emerging therapies, access considerations, and managed care implications in IgA nephropathy.

Live April 30 at 12 PM ET

Register free: https://t.co/KQlDCeQtOR

[First Report Managed Care @FirstReportMC]

Join us live on April 30 at 12 PM ET for a webinar on emerging therapies and managed care considerations in IgA nephropathy. Hear expert perspectives on access, evidence, and the evolving treatment landscape. Register now: https://t.co/ba2DEw2oYP

[First Report Managed Care @FirstReportMC]

Don’t miss tomorrow’s live webinar! Join Dr Saad Ashraf as he discusses how nerandomilast, the first new idiopathic pulmonary fibrosis (IPF) therapy in over a decade, is transforming care and access.

Free to register >>>
https://t.co/hzrKjfZ0pO

[First Report Managed Care @FirstReportMC]

Innovation in pulmonary fibrosis demands more than strategy. Hear from Dr Saad Ashraf on Monday, December 8 at 1 PM EST as he discusses how nerandomilast is redefining treatment and setting the stage for broader pulmonary fibrosis management.

Register >>>
https://t.co/WBM3dmSsb9

[First Report Managed Care @FirstReportMC]

How is new evidence changing pulmonary fibrosis care? Join Dr Saad Ashraf on Monday, December 8 at 1 PM EST for an expert discussion on nerandomilast and how it is shaping treatment decisions.

Register for Free >>>
https://t.co/fr3gp0EMu0

[First Report Managed Care @FirstReportMC]

Innovation in pulmonary fibrosis demands more than strategy. Hear from Dr Saad Ashraf on Monday, December 8 at 1 PM EST as he discusses how nerandomilast is redefining treatment and setting the stage for broader pulmonary fibrosis management.

Register >>>
https://t.co/owfiVX0tmd

[First Report Managed Care @FirstReportMC]

We’re going live tomorrow at 12:00 PM ET for our upcoming webinar From Innovation to Implementation: Rethinking Access in Idiopathic Pulmonary Fibrosis—will you be joining us?

Secure your spot here! → https://t.co/X7ZelqQPPh

[First Report Managed Care @FirstReportMC]

Are you registered for the upcoming idiopathic pulmonary fibrosis webinar on October 30? Join Elizabeth Volkmann, MD, and Carole Tremonti, RN, MBA, to learn more about clinical innovation.

https://t.co/w3CmslMqTX

[First Report Managed Care @FirstReportMC]

As new therapies for idiopathic pulmonary fibrosis (IPF) emerge, healthcare stakeholders must navigate the balance between innovation and evidence-based coverage decisions.

Register for this IPF webinar today! https://t.co/uIIapUAYfp

[First Report Managed Care @FirstReportMC]

Study authors examined the safety and effectiveness of pitolisant in #patients with type I narcolepsy who did not tolerate or respond to previous treatments. https://t.co/yjiTBP9NpX

[First Report Managed Care @FirstReportMC]

There's still time to register for the managed care considerations webinar on Addressing the Burdens of Alzheimer's Disease. Check out the two dates and times below! https://t.co/1L1dXIXldl

[First Report Managed Care @FirstReportMC]

Researchers assessed potential factors driving differences in #disease burden between African American and White patients with multiple sclerosis. https://t.co/gmbkN3Ia6t

[First Report Managed Care @FirstReportMC]

Patients with relapsing/remitting multiple sclerosis reported improvements in #medication satisfaction, fatigue, and other measures after switching from other therapies to a monoclonal antibody. https://t.co/3eMmf88DkC

[First Report Managed Care @FirstReportMC]

Happening soon! There's still time to register for today's webinar on managed care considerations for the treatment of tardive dyskinesia. Can't make it? Check out the other date below! https://t.co/N446xPphXs

[First Report Managed Care @FirstReportMC]

In the second part of this roundtable, Edmund Pezalla, MD, MPH; Adam Kittai, MD; Farrukh Awan, MD; and Jeffrey Dunn, PharmD, MBA, discuss cost and access challenges for treating #patients with zanubrutinib. https://t.co/En2LbR967M

[First Report Managed Care @FirstReportMC]

#ICYMI There is still time to register for tomorrow's Managed Care Considerations webinar happening at 1 p.m. https://t.co/MVJzHmOLOq

[First Report Managed Care @FirstReportMC]

In addition to the #Economic burden of the disease, researchers also reported the humanistic burden associated with pediatric-onset multiple sclerosis. https://t.co/AzpK9Nqwh5